Literature DB >> 12144573

The potential risk factors leading to peptic ulcer formation in autoimmune disease patients receiving corticosteroid treatment.

J-C Luo1, F-Y Chang, H-Y Lin, R-H Lu, C-L Lu, C-Y Chen, S-D Lee.   

Abstract

AIM: To study the potential risk factors leading to peptic ulcer disease among autoimmune disease patients on corticosteroid treatment.
METHODS: One hundred and thirty-eight corticosteroid-treated autoimmune disease patients were enrolled; their demographic data were recorded and laboratory data were measured. Endoscopy was performed to assess the occurrence of peptic ulcer disease. Helicobacter pylori infection was diagnosed on the basis of rapid urease test and histological examination.
RESULTS: Twenty-eight (20%) of 138 autoimmune disease patients had peptic ulcer disease, including 17 with gastric ulcer, eight with duodenal ulcer and three with gastric ulcer plus duodenal ulcer. Eighty five (62%) had used non-steroidal anti-inflammatory drugs and 46 (33%) had H. pylori infection. The majority of peptic ulcer disease subjects showed the following characteristics: age >or= 60 years; male; smokers; non-steroidal anti-inflammatory drug users, particularly the non-specific cyclo-oxygenase inhibitors; presence of hyperpepsinogenaemia I; low H. pylori colonization (P < 0.05). Multivariate analysis revealed that an age >or= 60 years [odds ratio (OR), 6.80; P = 0.001], smoking (OR, 7.94; P = 0.004) and the use of non-specific cyclo-oxygenase inhibitors (OR, 4.71; P = 0.030) were the predominant risk factors for the development of peptic ulcer disease among these patients, whereas H. pylori infection showed a protective role (OR, 0.20; P = 0.022).
CONCLUSIONS: Old age, smoking and the use of non-specific cyclo-oxygenase inhibitors are risk factors for peptic ulcer disease in autoimmune disease patients on corticosteroid treatment. H. pylori infection appears to protect against peptic ulcer disease in these patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12144573     DOI: 10.1046/j.1365-2036.2002.01279.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  Factors associated with the initiation of proton pump inhibitors in corticosteroid users.

Authors:  Jeffrey C Munson; Peter M Wahl; Gregory Daniel; Stephen E Kimmel; Sean Hennessy
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01-25       Impact factor: 2.890

2.  Hemophagocytic syndrome secondary to adult-onset Still's disease but very similar to lymphoma.

Authors:  Xin-Hua Zhang; Yong-Mei Han; Wen-Wen Wang; Hao Cheng; Ke-Jian Zhu
Journal:  Int J Clin Exp Pathol       Date:  2012-04-16

3.  Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy.

Authors:  Jiing-Chyuan Luo; Full-Young Chang; Tseng-Shing Chen; Yee-Yung Ng; Han-Chieh Lin; Ching-Liang Lu; Chih-Yen Chen; Hsiao-Yi Lin; Shou-Dong Lee
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 4.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.